Pharma Zydus begins human trials of Coronavirus vaccine; national tally nears 9.40L mark
Gujarat-based pharmaceutical company Zydus on Wednesday said that it has initiated human trials for potential Coronavirus vaccines. The vaccine ‘ZyCoV-D’ was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies
The Clinical Trial Registry of India (CTRI) said that the first phase where the vaccine will be tested for safety will be completed in 84 days while the second phase will be tested for safety, efficacy for another 84 days.
The company through a statement said, “Zydus has already manufactured clinical GMP batches of the vaccine candidate and plans to initiate the clinical trials in July 2020 across multiple sites in India in over 1000 subjects.”
Earlier this month, Zydus had announced that its plasmid DNA vaccine was developed at its Ahmedabad Vaccine Technology Centre and had completed the pre-clinical phase. The pharma company has also received a go ahead from the Drug Controller General of India (DCGI) to start human trial studies for the vaccine and with this, the company has become the second after Bharat Biotech to start human studies.
The trials will be conducted on 1,000 subjects in several clinical study sites across India which has a total of 9,36,181 Coronavirus cases. On Wednesday, 28,498 new cases were reported from different states in the last 24 hours. Maximum cases were registered from Maharashtra (6,741), Tamil Nadu (4,526) and Delhi (1,606).